SG143042A1 - Treatment for diabetes - Google Patents

Treatment for diabetes

Info

Publication number
SG143042A1
SG143042A1 SG200402994-8A SG2004029948A SG143042A1 SG 143042 A1 SG143042 A1 SG 143042A1 SG 2004029948 A SG2004029948 A SG 2004029948A SG 143042 A1 SG143042 A1 SG 143042A1
Authority
SG
Singapore
Prior art keywords
treatment
diabetes
kit
ingredient
patient
Prior art date
Application number
SG200402994-8A
Other languages
English (en)
Inventor
Indu Parikh
Anne Lane
Ronald V Nardi
Stephen J Brand
Original Assignee
Gen Hospital Corp
Waratah Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Waratah Pharmaceuticals Inc filed Critical Gen Hospital Corp
Publication of SG143042A1 publication Critical patent/SG143042A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/595—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
SG200402994-8A 1999-01-29 1999-10-27 Treatment for diabetes SG143042A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/241,100 US6558952B1 (en) 1992-12-14 1999-01-29 Treatment for diabetes

Publications (1)

Publication Number Publication Date
SG143042A1 true SG143042A1 (en) 2008-06-27

Family

ID=22909247

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200402994-8A SG143042A1 (en) 1999-01-29 1999-10-27 Treatment for diabetes

Country Status (11)

Country Link
US (4) US6558952B1 (ko)
EP (1) EP1071447A1 (ko)
JP (2) JP2004506591A (ko)
KR (2) KR20010074466A (ko)
CN (2) CN100482686C (ko)
AU (2) AU774746B2 (ko)
CA (1) CA2326741A1 (ko)
IL (1) IL138784A0 (ko)
SE (1) SE0003508L (ko)
SG (1) SG143042A1 (ko)
WO (1) WO2000044400A1 (ko)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
US20020099008A1 (en) 1999-04-26 2002-07-25 Daniel R. Twardzik Method for stimulating hematopoiesis using tgf-alpha
CA2371241A1 (en) 1999-04-26 2000-11-02 Stem Cell Pharmaceuticals, Inc. Tgf-.alpha. polypeptides, functional fragments and methods of use therefor
EP1210102B1 (en) * 1999-08-19 2010-04-07 Applied Protein Sciences, LLC Tgf-alpha polypeptides, functional fragments and methods of use therefor
US20020193301A1 (en) 1999-08-19 2002-12-19 Stem Cell Pharmaceuticals, Inc. TGF-alpha polypeptides, functional fragments and methods of use therefor
US6815418B2 (en) 1999-08-19 2004-11-09 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
US6677307B2 (en) 1999-08-19 2004-01-13 Kaleidos Pharma, Inc. TGF-α polypeptides, functional fragments and methods of use therefor
JP2004520345A (ja) * 2001-01-12 2004-07-08 ワラター・ファーマシューティカルズ・インク 糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
AU2003210959A1 (en) * 2002-02-12 2003-09-04 Cornell Research Foundation, Inc. Identification and high-yield isolation of human pancreatic islet progenitor and stem cells
US20060234373A1 (en) * 2002-05-24 2006-10-19 Alex Rabinovitch Treatment for diabetes
DE60329724D1 (de) * 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
EP1837031B1 (en) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
US20040209801A1 (en) * 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
US7025791B2 (en) 2002-12-02 2006-04-11 Gi Dynamics, Inc. Bariatric sleeve
WO2004096853A1 (en) * 2003-04-30 2004-11-11 Waratah Pharmaceuticals, Inc. Combined use of keratinocyte growth factor agonists and gastrin compounds
CN1829528A (zh) * 2003-05-27 2006-09-06 瓦拉塔药品公司 包含胃泌素化合物的组合物及其在糖尿病中的应用
US20080039379A1 (en) * 2003-05-27 2008-02-14 Waratah Pharmaceuticals, Inc. Compositions Comprising Gastrin Compounds and Their Use in Diabetes
WO2004106921A2 (en) * 2003-05-27 2004-12-09 Mcgill University In vitro platform for screening agents inducing islet cell neogenesis
RU2006131046A (ru) * 2004-01-30 2008-03-10 Уэрейта Фармасьютикалз, Инк. (Ca) Совместное применение агониста glp-1 и соединений гастрина
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1765873A4 (en) * 2004-07-01 2009-07-01 Waratah Pharmaceuticals Inc COMBINED USE OF CD3 AGONIST AND GASTRIN FOR THE TREATMENT OF DIABETES
WO2007022123A2 (en) * 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
EP1951286A4 (en) * 2005-10-07 2009-11-04 Waratah Pharmaceuticals Inc COMBINED USE OF INHIBITORS OF DPP-IV AND GASTRIN COMPOUNDS
US8093038B2 (en) * 2007-09-17 2012-01-10 Illinois Institute Of Technology Apparatus and method for encapsulating pancreatic cells
WO2010002492A1 (en) * 2008-04-29 2010-01-07 University Of Chicago Methods of use of adenine derivatives for the treatment of diabetes and other disorders
JP5838557B2 (ja) * 2010-07-05 2016-01-06 ソニー株式会社 生体情報処理方法および装置、並びに記録媒体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464363A (en) * 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
EP0239716B1 (en) * 1986-01-10 1993-03-31 Alfio Bertolini Pharmaceutical compositions containing peptides of the cholecystokinin-cerulein group for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies
WO1995019785A1 (en) * 1994-01-24 1995-07-27 Research Triangle Pharmaceuticals Ltd. Treatment for juvenile diabetes
WO1996011701A1 (en) * 1994-10-14 1996-04-25 Glaxo Wellcome Inc. Enteric coated compositions of 1,5-benzodiazepine derivatives having cck antagonistic or agonistic activity
WO1997025030A1 (en) * 1996-01-08 1997-07-17 Astra Aktiebolag Multiple unit effervescent dosage forms comprising protonpump inhibitor

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE38892B1 (en) * 1973-03-28 1978-06-21 Ici Ltd Pharmaceutical compositions
JPS6028994A (ja) * 1983-07-08 1985-02-14 Wakunaga Seiyaku Kk 〔２１―ロイシン〕ヒトウロガストロン
FR2575163B1 (fr) * 1984-12-20 1987-03-20 Sanofi Sa Tri- et tetrapeptides reduits inhibiteurs de la secretion gastrique, procede d'obtention et compositions pharmaceutiques les contenant
US4686283A (en) * 1985-04-16 1987-08-11 Syntex (U.S.A.) Inc. Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
EP0284898A3 (de) * 1987-04-02 1990-06-27 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Hinge-Peptid, Verfahren zu seiner Herstellung und seine Verwendung zur Herstellung synthetischer Immunogene
US5102789A (en) * 1989-03-15 1992-04-07 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of epideramal growth factor in pichia pastoris yeast cells
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
US4997950A (en) * 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
US5158935A (en) * 1989-05-12 1992-10-27 Chiron Corporation Human epidermal growth factor having substitution at position 11
IE68593B1 (en) * 1989-12-06 1996-06-26 Sanofi Sa Heterocyclic substituted acylaminothiazoles their preparation and pharmaceutical compositions containing them
DK0541726T3 (da) * 1990-08-02 2000-08-21 Indu Parikh Vækstfaktorsammensætninger, fremstilling og anvendelse
US5434135A (en) * 1990-08-02 1995-07-18 Indu Parikh Growth factor compositions, preparation and use
US5468727A (en) * 1990-12-13 1995-11-21 Board Of Regents, The University Of Texas System Methods of normalizing metabolic parameters in diabetics
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
EP0586549B1 (en) * 1991-05-10 2000-09-20 Genentech, Inc. Selecting ligand agonists and antagonists
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5290920A (en) * 1992-04-16 1994-03-01 Allelix Biopharmaceuticals Inc. Method of purifying human epidermal growth factor
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US5624895A (en) * 1994-02-18 1997-04-29 Georgetown University Medical Center Treatment and/or prevention of type I diabetes mellitus with gamma interferon administration
US5587309A (en) * 1994-04-29 1996-12-24 The United States Of America As Represented By The Department Of Health And Human Services Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo
WO1995029690A1 (en) * 1994-04-29 1995-11-09 The Trustees Of The University Of Pennsylvania Biologically active peptides and methods of identifying the same
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US6346390B1 (en) * 1996-03-08 2002-02-12 Receptron, Inc. Receptor derived peptides involved in modulation of response to ligand binding
JP2001521897A (ja) * 1997-10-31 2001-11-13 スミスクライン・ビーチャム・コーポレイション 新規な金属錯体
EP1049486A4 (en) * 1997-12-05 2006-01-04 Lilly Co Eli GLP-1 FORMULATIONS
ATE361098T1 (de) * 1998-05-15 2007-05-15 Receptor Biologix Inc Vorbeugung und behandlung von hypergastrinemie
JP2003522105A (ja) * 1998-06-18 2003-07-22 チョワース、ミッチャル、ワイ． ヘリコバクター・ピロリ（Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ）関連疾患治療用医薬組成物
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
EP1306091A3 (en) * 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation of beta cell proliferation
US6242666B1 (en) * 1998-12-16 2001-06-05 The Scripps Research Institute Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
CA2362593A1 (en) * 1999-02-10 2000-08-17 Curis, Inc. Pancreatic progenitor cells, methods and uses related thereto
US6815203B1 (en) * 1999-06-23 2004-11-09 Joslin Diabetes Center, Inc. Methods of making pancreatic islet cells
AU778929B2 (en) * 1999-12-06 2004-12-23 General Hospital Corporation, The Pancreatic stem cells and their use in transplantation
EP1265985A4 (en) * 2000-02-18 2004-06-23 Inst Medical W & E Hall PANCREAS ISLAND CELL GROWTH FACTORS
JP2004520345A (ja) * 2001-01-12 2004-07-08 ワラター・ファーマシューティカルズ・インク 糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続
CA2442177A1 (en) * 2001-03-29 2002-10-10 Ixion Biotechnology, Inc. Method for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway
WO2002096203A1 (en) * 2001-05-25 2002-12-05 Cythera, Inc. Stem cell differentiation
US20030119734A1 (en) * 2001-06-28 2003-06-26 Flink James M. Stable formulation of modified GLP-1
US20030049236A1 (en) * 2001-07-27 2003-03-13 Arhus Amt Immortalized stem cells
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
WO2003050249A2 (en) * 2001-12-07 2003-06-19 Geron Corporation Islet cells from human embryonic stem cells
US20060234373A1 (en) * 2002-05-24 2006-10-19 Alex Rabinovitch Treatment for diabetes
EP1837031B1 (en) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
DE60329724D1 (de) * 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln
US20040209801A1 (en) * 2002-10-22 2004-10-21 Brand Stephen J. Treatment of diabetes
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464363A (en) * 1979-12-20 1984-08-07 Merck & Co., Inc. Ajuvants for rectal delivery of drug substances
EP0239716B1 (en) * 1986-01-10 1993-03-31 Alfio Bertolini Pharmaceutical compositions containing peptides of the cholecystokinin-cerulein group for the therapy of shock conditions and of respiratory and cardiocirculatory insufficiencies
WO1995019785A1 (en) * 1994-01-24 1995-07-27 Research Triangle Pharmaceuticals Ltd. Treatment for juvenile diabetes
WO1996011701A1 (en) * 1994-10-14 1996-04-25 Glaxo Wellcome Inc. Enteric coated compositions of 1,5-benzodiazepine derivatives having cck antagonistic or agonistic activity
WO1997025030A1 (en) * 1996-01-08 1997-07-17 Astra Aktiebolag Multiple unit effervescent dosage forms comprising protonpump inhibitor

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUNCTION AND REGULATION OF GASTRIN IN TRANSGENIC MICE: A REVIEW *
PANCREATIC GASTRIN STIMULATES ISLET DIFFERENTIATION OF TRANSFORM *

Also Published As

Publication number Publication date
JP2004506591A (ja) 2004-03-04
CN101524530A (zh) 2009-09-09
JP2008094854A (ja) 2008-04-24
EP1071447A1 (en) 2001-01-31
IL138784A0 (en) 2001-10-31
SE0003508L (sv) 2000-11-21
AU2004218687A1 (en) 2004-11-04
US20040209816A1 (en) 2004-10-21
KR20050096212A (ko) 2005-10-05
AU774746B2 (en) 2004-07-08
KR20010074466A (ko) 2001-08-04
CN1308544A (zh) 2001-08-15
SE0003508D0 (sv) 2000-09-29
WO2000044400A1 (en) 2000-08-03
US20020081285A1 (en) 2002-06-27
US20090041731A1 (en) 2009-02-12
AU2004218687B2 (en) 2008-02-21
CA2326741A1 (en) 2000-08-03
CN100482686C (zh) 2009-04-29
AU1331900A (en) 2000-08-18
US6558952B1 (en) 2003-05-06

Similar Documents

Publication Publication Date Title
SG143042A1 (en) Treatment for diabetes
HUP0200556A3 (en) Medicament for treating diabetes
HK1031201A1 (en) Mixing/charging port for medical treatment.
HK1048427A1 (en) Drug delivery device.
IL138990A0 (en) Matrices for drug delivery and methods for making and using the same
IL151202A0 (en) Phenyl derivatives, a process for their praparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy
HUP0002628A2 (en) Pharmaceutical combinations for treating diabetes
EP1194173A4 (en) ADMINISTRATION OF MEDICINE GUIDED BY X-RAY
ZA962536B (en) Pharmaceutical composition for transdermal administration.
IL144728A0 (en) Iontophoresis, electroporation and combination patches for local drug delivery
PL357535A1 (en) Hydrogel-driven drug dosage form
MY125978A (en) Admantane derivatives
IL161682A0 (en) A medicament container, a medicament dispensing kit for administering medication and a method for packaging the same
HK1040679A1 (zh) 裝兩種分開的、不穩定物質的藥物容器
HK1033278A1 (en) Pharmaceutical preparation for use in anti-asthma therapy.
HK1009814A1 (en) Five-membered heterocycles having biphenylsulfonylsubstitution, process for their prparation, their use as a medicament or diagnostic, and medicament .
GB2314022B (en) Blending medical composition with sustained medicament releasability and process for preparing the same
AU4612300A (en) Preventive or therapeutic drugs for diabetes
ZA972147B (en) Dimethyl-(3-aryl-but-3-enyl)-amine compounds as pharmaceutical active ingredients.
HUP0201047A2 (en) Steroid compounds with a c17-alkyl side chain and an aromatic a-ring, process for their preparation and pharmaceutical compositions containing the compounds
HUP0103852A2 (hu) Összeállítás egészségügyi folyadék tárolására és bejuttatására
HK1044725A1 (en) Mixing/charging port for medical treatment.
ZA974665B (en) Substituted 2-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them.
ZA989781B (en) Novel bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them.
HUP0203695A3 (en) Substituted pyrrole mannich bases preparation and use thereof, and pharmaceutical composition containing the same